EMD Serono Research & Development Institute, Inc.
$1.7M 80 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. reported $1,669,960.78 across General Payments, Research, and Ownership to 28,289 physicians and teaching hospitals across 28,319 transactions.
- $1.7M Above-median payer
- All-tracks total
- 28,319 Top 10% volume
- Transactions
- 28,289 Top 10% reach
- Recipients
- +$36.8K
- General Payments vs PY2023
Xeris Pharmaceuticals, Inc. reported $1,669,960.78 across all CMS Open Payments tracks (General + Research + Ownership) to 28,289 physicians and teaching hospitals in Program Year 2024 - ranking #493 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,174,861.27, averaging $59.03 per recipient.
How Xeris Pharmaceuticals, Inc.'s $1.7M all-tracks total breaks down
Xeris Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
72/100
Total payments
F
25/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer xeris-pharmaceuticals-inc Xeris Pharmaceuticals, Inc.
$1.7M · #493/1,925 · 0.0% industry · PY2024
- TOT $1.7M
- RANK #493
- SHARE 0.0%
- TXN 28,319
- RCP 28,289
- CAT 5
- GEN $1.2M
- ΔGEN +$36.8K
- TOP1 5.3%
- PY 2024
Volume peers
Nearest volume peer: EMD Serono Research & Development Institute, Inc. ($1.7M)
Xeris Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Xeris Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $36.8K (+3.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: XERIS PHARMACEUTICALS, INC.PY2023: XERIS PHARMACEUTICALS, INC.PY2024: Xeris Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,138,033.80
- PY2024
- $1,174,861.27
What the Data Shows for Xeris Pharmaceuticals, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Xeris Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $598.1K, accounting for 50.9% of this company's General Payments and 27,679 transactions.
General Payment Breakdown by Type
Xeris Pharmaceuticals, Inc. made 5 types of general payments. "Food and Beverage" is the largest category at $598.1K, 50.9% of General Payments.
Xeris Pharmaceuticals, Inc. reports 5 general-payment categories - the top three are Food and Beverage (50.9%), Honoraria (35.5%), and Travel and Lodging (5.5%). The remaining 2 categories make up 8.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Xeris Pharmaceuticals, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $598.1K | 27,679 | 50.9% |
| Honoraria | $416.6K | 241 | 35.5% |
| Travel and Lodging | $65.0K | 253 | 5.5% |
| Consulting Fee | $60.9K | 14 | 5.2% |
| Education | $34.2K | 102 | 2.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $230,762.90 (19.6%) of $1,174,861.27 in this company's General Payments records across 12,975 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Xeris Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Jeffrey Sherman
$62,772.50 across 25 reported transactions
- 2
Philip Rabito
$60,674.92 across 77 reported transactions
- 3
John Paes
$38,402.04 across 52 reported transactions
- 4
Elena Christofides
$37,389.19 across 57 reported transactions
- 5
Jessica R Adkins
$31,524.25 across 63 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Xeris Pharmaceuticals, Inc. ranks #493 of 1,925 by total payments (top 26% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,680 of 1,838 by HHI (bottom 9% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Array Biopharma Inc : $400.2K total payments, HHI 112
- Travere Therapeutics, Inc. : $2.0M total payments, HHI 112
- Avion Pharmaceuticals : $3.5K total payments, HHI 112
- Dompe US, Inc. : $1.3M total payments, HHI 111
- ADC Therapeutics America, Inc. : $1.1M total payments, HHI 111
- Kyowa Kirin, Inc. : $2.5M total payments, HHI 111
- Xeris Pharmaceuticals, Inc. (this company) : $1.2M total payments, HHI 110
- Mallinckrodt Hospital Products Inc. : $7.6M total payments, HHI 109
- Lexicon Pharmaceuticals, Inc. : $2.5M total payments, HHI 108
- Nevro Corp. : $2.5M total payments, HHI 107
- Almatica Pharma LLC : $421.9K total payments, HHI 106
- Vifor Pharma, Inc. : $368.6K total payments, HHI 106
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Xeris Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Xeris Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Xeris Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Sebela Women's Health Inc.
$1.7M 19 recipients
Compare payment profiles
KARL STORZ Endoscopy-America
$1.7M 1,585 recipients
Compare payment profiles
Gen-Probe, Inc.
$1.6M 250 recipients
Compare payment profiles
ABK Biomedical USA, Inc.
$1.6M 49 recipients
Compare payment profiles
Patterson Companies, Inc.
$1.7M 7,273 recipients
Compare payment profiles
Put this to use
Xeris Pharmaceuticals, Inc. ranks #493 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Xeris Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Xeris Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.